Used in targeted cancer therapy, particularly for tumors exhibiting dysregulated c-MET signaling pathway activity. Binds specifically to the extracellular domain of the c-MET receptor, blocking hepatocyte growth factor (HGF) interaction and inhibiting downstream signaling involved in tumor growth, invasion, and metastasis. Investigated in clinical trials for non-small cell lung cancer, gastric cancer, and other solid tumors, often in combination with other targeted agents or chemotherapy. Designed for intravenous administration as a humanized monoclonal antibody to minimize immunogenicity while enhancing therapeutic efficacy.